Diana Bernstein is a Director at Northpond Ventures, focusing on investments in therapeutics. She holds a Ph. D. in Pharmacology from the University of Pennsylvania and a B. S. from the University of Maryland. Her previous experience includes roles at Vida Ventures and Merck, shaping her expertise in biopharma.
She believes in technologies that can redefine the treatment of neurodegenerative diseases by targeting the epigenetic basis of the illness.
Diana Bernstein, Ph.D.
Director at Northpond Ventures
Cambridge, Massachusetts, United States
Overview
Topics They Care About
Therapeutic Investing
As a Director at Northpond Ventures, she leads investments and serves on the boards of innovative therapeutics companies like Mestag and Code Biotherapeutics.
Neurodegenerative Diseases
Publicly supports new approaches to treating neurodegenerative diseases, specifically through technologies that target the epigenetic basis of the condition.
Immunology & Rare Diseases
Actively involved with portfolio companies like OMass that are focused on addressing challenging drug targets in immunology and rare diseases.
Media Appearances
Diana has no verified media appearances
Work History
12-2024
Director at Northpond Ventures
1-2023 - 12-2024
Principal at Northpond Ventures
6-2021 - 1-2023
Vice President at Northpond Ventures
12-2022
Board Director at Mestag Therapeutics
6-2022
Board Director at Code Biotherapeutics
5-2022
Board Director at OMass Therapeutics
12-2022 - 1-2024
Board Director at CAMP4 Therapeutics
Education
BS from University of Maryland
PhD from University of Pennsylvania
More Information
Social Presence :
Prographics :
Exp : 4
Location : Cambridge, Massachusetts, United States
Job Level : Mid-senior
Designation : Director at Northpond Ventures
